| Name | Title | Contact Details |
|---|
With a track record of transformative leadership in healthcare technology, Figueroa will spearhead our efforts to integrate cutting-edge technology, streamline operations, and enhance patient care across our extensive network of community-based clinics.As a dynamic leader, Figueroa brings a wealth of experience in leveraging technology to optimize healthcare delivery. His strategic vision aligns perfectly with our commitment to providing the best possible care to our patients. He will play a pivotal role in advancing our digital infrastructure, fostering innovation, and ultimately, improving outcomes for those we serve.
Seagrove Inc. is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Diversified Clinical Services is a privately held corporation headquartered in Jacksonville, Florida, with offices in Tustin, CA and the Woodlands, TX. The company was formed as a result of a merger between Diversified Therapy and Praxis Clinical
UConn Health is a vibrant, integrated academic medical center that is entering an era of unprecedented growth in all three areas of its mission: academics, research, and clinical care. UConn Health is at the center of Bioscience Connecticut, a bold plan introduced by Connecticut Governor Dannel P. Malloy and approved by the Connecticut General Assembly in 2011. The plan will strengthen Connecticut`s position as a national and global leader for bioscience innovation and improve access to quality health care for Connecticut citizens for generations to come. Based in Farmington, Connecticut – a popular suburb of the state`s capitol of Hartford – UConn Health is home to the School of Medicine, School of Dental Medicine, John Dempsey Hospital, UConn Medical Group, UConn Health Partners, University Dentists and a thriving research enterprise. With approximately 5,000 employees, UConn Health is a major economic driver in the region, generating nearly $1 billion annually in gross state product. It is closely linked with the University of Connecticut`s main campus in Storrs through multiple, cross-campus academic projects.
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).